Loading organizations...
Key people at CCRM.
Founded in 1987 by chief medical officer William Schoolcraft, Lone Tree, Colorado-based CCRM Fertility provides advanced treatments like in vitro fertilization, egg freezing, third-party reproduction, and preimplantation genetic testing. Operating under a fee-for-service business model, the organization manages 34 clinic locations across 11 major metropolitan areas throughout the United States and Canada. The clinical network employs prominent reproductive specialists, including IVF pioneer David Meldrum, Dallas-Fort Worth partner Marius Meintjes, and Miami founding physician Callum Potts. In June 2022, the company expanded its operational footprint by acquiring The Institute for Reproductive Medicine & Science, a strategic transaction adding 11 doctors and eight regional offices across New Jersey and New York. Utilizing specialized in-house laboratories to manage comprehensive reproductive medicine services, the fertility network has successfully facilitated the conception of over 100,000 babies to date.
Key people at CCRM.
CCRM (Centre for Commercialization of Regenerative Medicine) is a Canadian not-for-profit, public-private consortium dedicated to accelerating the commercialization of regenerative medicines, including cell and gene therapies.[1][2][5][6] Its mission is to generate sustainable health and economic benefits through global collaboration in cell and gene therapy and regenerative medicine, with a vision to become the premier global enabler of clinically-tested therapies and foundational technologies.[1][2][5] CCRM bridges the gap from research to market by providing strategic funding, dedicated infrastructure like GMP facilities, contract manufacturing services, and multidisciplinary incubation teams that match technologies with market needs.[1][2][5] It partners with over 45 industry companies, academic institutions, and investors, launching ventures, scaling companies, and attracting enterprises to transform healthcare for debilitating diseases.[2][5][6]
As a key player in the startup ecosystem, CCRM catalyzes investment, supports spin-offs like ExCellThera, and operates GMP facilities in collaboration with entities like Sunnybrook Research Institute and University Health Network, fostering innovation in cell manufacturing, process development, and therapy delivery.[1][2][6]
CCRM was launched in June 2011 as a Centre of Excellence for Commercialization and Research (CECR), funded by the Government of Canada’s Networks of Centres of Excellence program, seven Canadian institutional partners, and industry contributors.[2][6] It emerged from a recognized need to unify business leadership, scientific expertise, and infrastructure to commercialize stem cell, biomaterials, and regenerative technologies that were stalled in translation.[6] Co-led by Chief Scientific Officer Dr. Peter Zandstra, a Canada Research Chair in Stem Cell Bioengineering, and former President and CEO Dr. Michael May, CCRM quickly built momentum through partnerships, including a CDN $40 million grant with GE Healthcare for cell therapy manufacturing and the opening of GMP facilities in 2017 with University Health Network.[2]
Its evolution has focused on expanding global networks, with initiatives like incubation teams and international platforms, leading to over 10 co-development projects and spin-outs by 2018.[1][2][5]
CCRM rides the explosive growth in regenerative medicine, particularly cell and gene therapies targeting cancers, degenerative diseases, and immune disorders, amid a market projected to transform healthcare economics.[1][5] Its timing aligns with advances in stem cell engineering, scalable manufacturing, and GMP standards, addressing bottlenecks like high costs and translation failures that have historically delayed therapies.[2][6] Favorable forces include government funding for bio-innovation, rising investor interest in biotech, and global demand for curative treatments over chronic management.[1][2] By creating a "nexus" for translation, CCRM influences the ecosystem through spin-outs, co-developments, and platforms like Medicine by Design, democratizing access to cutting-edge tech and positioning Canada as a regenerative medicine hub.[5][6]
CCRM is poised to expand its GMP infrastructure and global consortium, potentially launching more spin-offs in scalable T-cell and stem cell platforms amid surging demand for personalized therapies.[1][5] Trends like AI-driven biomanufacturing, international clinical trial networks, and policy support for cell/gene approvals will amplify its role, evolving it from a Canadian accelerator to a worldwide enabler of revolutionary medicines.[2][4] As regenerative tech matures, CCRM's collaborative model will likely drive broader ecosystem impact, turning foundational discoveries into widespread health solutions that echo its core mission of sustainable benefits.
